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Abstract
BACKGROUND—Human papillomavirus (HPV) vaccines can potentially prevent greater than 
90% of cervical and anal cancers as well as a substantial proportion of vulvar, vaginal, penile, and 
oropharyngeal cancers caused by certain HPV types. Because more than 38,000 HPV-associated 
cancers are diagnosed annually in the United States, current studies are needed to understand how 
relative survival varies for each of these cancers by certain demographic characteristics, such as 
race and age.
METHODS—The authors examined high-quality data from 27 population-based cancer registries 
covering approximately 59% of the US population. The analyses were limited to invasive cancers 
that were diagnosed during 2001 through 2011 and followed through 2011 and met specified 
histologic criteria for HPV-associated cancers. Five-year relative survival was calculated from 
diagnosis until death for these cancers by age, race, and sex.
RESULTS—The 5-year age-standardized relative survival rate was 64.2% for cervical 
carcinomas, 52.8% for vaginal squamous cell carcinomas (SCCs), 66% for vulvar SCCs, 47.4% 
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for penile SCCs, 65.9% for anal SCCs, 56.2% for rectal SCCs, and 51.2% for oropharyngeal 
SCCs. Five-year relative survival was consistently higher among white patients compared with 
black patients for all HPV-associated cancers across all age groups; the greatest differences by race 
were observed for oropharyngeal SCCs among those aged <60 years and for penile SCCs among 
those ages 40 to 49 years compared with other age groups.
CONCLUSIONS—There are large disparities in relative survival among patients with HPV-
associated cancers by sex, race, and age. HPV vaccination and improved access to screening (of 
cancers for which screening tests are available) and treatment, especially among groups that 
experience higher incidence and lower survival, may reduce disparities in survival from HPV-
associated cancers.
Keywords
human papillomavirus (HPV) cancer; HPV-associated cancer; HPV-associated cancer; relative 
survival
INTRODUCTION
Human papillomavirus (HPV) infection is the most common sexually transmitted infection 
among men and women in the United States, with approximately 14 million new infections 
occurring each year.1 Persistent infections with high-risk HPV (including HPV types 16, 18, 
31, 33, 45, 52, and 58) cause nearly all cervical cancers and a substantial proportion of other 
cancers.2,3 HPV-associated cancers can be defined as invasive cancers at anatomic sites 
(cervix, vulva, vagina, penis, oropharynx, anus, and rectum) with cell types in which HPV 
DNA is frequently identified—all carcinomas of the cervix, including adenocarcinomas and 
squamous cell carcinomas (SCCs), and SCCs only for the other anatomic sites. A recent 
genotyping study estimated that HPV DNA was present in 91% of cervical cancers, 75% of 
vaginal cancers, 69% of vulvar cancers, 91% of anal cancers, 63% of penile cancers, and 
71% oropharyngeal cancers.4 However, cancer registries do not routinely collect information 
on the presence of HPV DNA in cancer tissues. Therefore, to estimate the number of cancers 
attributed to HPV, the Centers for Disease Control and Prevention (CDC) multiplied the 
number of HPV-associated cancers by the percentage of each cancer type attributable to 
HPV based on the genotyping study. On the basis of these attributable fractions, 79% of the 
38,793 “HPV-associated cancers” diagnosed annually in the United States during 2008 
through 2012 could be attributed to HPV.5
Many studies to date have focused on cervical cancers, because almost all of these cancers 
are associated with HPV infection. Furthermore, cervical and oropharyngeal cancers account 
for greater than one-half of all HPV-associated cancers.5 However, in recent years, 
considerable attention has been given to oropharyngeal cancers and the role of HPV 
infection in these cancers. Although many studies have focused on the incidence of HPV-
associated cancers, very few have examined survival, and most of these have focused on 
cervical and oropharyngeal cancers.3,5–8 Survival reports on less common HPV-associated 
cancers, such as vaginal, vulvar, penile, anal, and rectal malignancies, are lacking. Thus, to 
better understand survival in HPV-associated cancers in the United States along with any 
disparities by sex, race, or age that may exist, the objective of this study was to examine 
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survival among patients diagnosed with HPV-associated cancers using data from the CDC’s 
National Program of Cancer Registries (NPCR) from 2001 through 2011.
MATERIALS AND METHODS
The NPCR data set includes cancer incidence data from central cancer registries funded by 
the NPCR in 45 states, the District of Columbia, and Puerto Rico.9 Data on all new 
diagnoses of cancer from patient records at such medical facilities as hospitals, physicians’ 
offices, therapeutic radiation facilities, freestanding surgical centers, and pathology 
laboratories are reported to central cancer registries, which collate these data and use state 
vital records to collect information about any cancer deaths that were not reported as cases. 
The central cancer registries use uniform data items and codes as documented by the North 
American Association of Central Cancer Registries. These data are submitted annually in 
November to the CDC and are combined into 1 data set. Cancer registries demonstrate that 
data are of high quality by meeting US Cancer Statistics publication criteria. Information on 
primary site and histology is coded according to the International Classification of Diseases 
for Oncology, Third Edition and categorized according to the revised Surveillance, 
Epidemiology, and End Results (SEER) recodes dated January 27, 2003, which define 
standard groupings of primary cancer sites (available at; https://seer.cancer.gov/siterecode 
accessed December, 2016). The data include information about diagnostic confirmation of 
each case, including whether histologic type was determined by microscopic examination of 
tumor tissue.
For the current analysis we used survival data for invasive cancer cases diagnosed during 
2000 through 2011 using the NPCR November 2014 data submission.10 We limited our 
analysis to registries that met the NPCR data-quality standards for inclusion in US Cancer 
Statistics publications11 and also performed active patient follow-up or linkage with the 
National Death Index. These 27 registries represent 59% of the US population.
We limited our analysis to invasive cancers that were microscopically confirmed and met 
specified histologic criteria for HPV-associated cancers using the same framework as in 
prior studies.7,12 Cancers were classified by anatomic site using International Classification 
of Diseases for Oncology, Third Edition codes.13 All epithelial carcinomas (histology codes 
8010-8671 and 8940-8941) were included for cervical cancers (site codes C53.0-C53.9).14 
For other sites, we included SCCs (histology codes 8050-8084 and 8120-8131) for sites in 
the vulva (site codes C51.0-C51.9), vagina (site code C52.9), penis (site codes C60.0-60.9), 
anus and rectum (site codes C21.0-C21.9 and C20.9), and certain subsites of the oropharynx 
(site codes C01.9, C02.4, C02.8, C05.1, C05.2, C09.0, C09.1, C09.8, C09.9, C10.0, C10.1, 
C10.2, C10.3, C10.4, C10.8, C10.9, C14.0, C14.2, and C14.8).5 Oropharyngeal subsites 
(including the base of tongue; pharyngeal tonsils, anterior and posterior tonsillar pillars, and 
glossotonsillar sulci; anterior surface of soft palate and uvula; and lateral and posterior 
pharyngeal walls) were based on sites in which HPV DNA is frequently identified.
4,5,7,12,14–17
 Although rectal SCC was not included in the genotyping study,4 we included it 
in this analysis, because recent studies indicate that rectal SCCs, although rare, are similar to 
anal SCCs and probably misclassified anal SCCs, and are likely to be HPV-associated.3,18
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By using sex-specific and state-specific life tables for all races and black and white race 
from the National Center for Health Statistics, we calculated 5-year relative survival 
percentages for patients diagnosed during 2001 through 2011 on all those who had follow-
up through 2011. Relative survival was defined as the ratio of the observed all-cause survival 
in a group of individuals with cancer to the expected all-cause survival of the general 
population. For this study, 5-year relative survival was calculated using the Ederer II relative 
survival method.19 Relative survival was calculated for each of the HPV-associated cancers 
by age at diagnosis, race, sex, and SEER Summary Stage 2000 (local, regional, distant). For 
patients who had multiple HPV-associated cancers diagnosed during the study period, all 
cancers were included in the analysis. All analyses were age-standardized using the 
International Cancer Survival Standard.20 Survival was calculated only for white and black 
racial groups, because expected life tables were not available for other racial/ethnic groups. 
SEER*Stat software version 8.3.2 was used for analysis.21
Survival estimates were calculated as a ratio and estimates with counts <25 suppressed. 
Formal statistical testing for pairwise comparisons was not performed to avoid multiple 
comparison problems. Ninety-five percent confidence intervals (95% CIs) are provided to 
allow for informal comparisons of survival estimates. Although examining overlap between 
CIs to determine differences in estimates is conservative, the sample sizes from more than 
10 years of national data are generally large for most groups.
RESULTS
In total, 220,211 HPV-associated cancers were diagnosed during 2001 through 2011, and the 
majority consisted of oropharyngeal SCCs (OPSCCs) and cervical carcinomas (36.4% and 
36.1%, respectively) followed by anal SCCs (11.8%) (Table 1). When comparing survival by 
cancer site, 5-year age-standardized relative survival was highest for vulvar and anal SCCs 
(66% and 65.9%, respectively) and lowest for penile and oropharyngeal SCCs (47.4% and 
51.2%, respectively) compared with other sites (Table 2).
For many HPV-associated cancers, 5-year age-standardized relative survival decreased with 
increasing age at diagnosis; however, we observed slightly increased survival for cancers 
diagnosed among those ages 40 to 49 years compared with those aged <40 years at the time 
of diagnosis for vaginal SCCs (66.6% and 62.7%, respectively), vulvar SCCs (85.9% and 
84.5%, respectively), and anal SCCs (72.6% and 66.1%, respectively). Survival consistently 
decreased with increasing age for cervical carcinomas, penile SCCs, and OPSCCs (Table 2). 
The difference in 5-year relative survival was at least 10% higher for those aged <40 years at 
the time of diagnosis compared with those aged ≥60 years at the time of diagnosis for all 
HPV-associated cancers, with the exception of anal SCCs, in which the difference was <2% 
(Table 2). A greater percentage of cases were diagnosed at older ages for most cancer types, 
except cervical cancer (73% were diagnosed at age <60 years), anal cancer (53% were 
diagnosed at aged <60 years), and oropharyngeal cancer (51% were diagnosed at age <60 
years).
Most of our study population was white (83%). More than 85% of each of the HPV-
associated cancers were diagnosed among whites, with the exception of cervical carcinomas 
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and vaginal SCCs, in which smaller proportions were diagnosed among whites (77.2% and 
80.9%, respectively) (Table 1). Five-year age-standardized relative survival was consistently 
higher for whites compared with blacks for all HPV-associated cancers, with higher survival 
observed for cervical carcinomas (64.8% and 57%, respectively), penile SCCs (48.4% and 
34.7%, respectively), anal SCCs (69.3% and 59.8%, respectively), rectal SCCs (61.2% and 
45.5%, respectively), and OPSCCs (53.5% and 32.4%, respectively) (Table 2). The lowest 
survival and the greatest differences by race were observed for blacks compared with whites 
for OPSCCs and penile SCCs (32.4% vs 53.5% and 34.7% vs 48.4%, respectively) (Table 
2).
When examining survival by age at diagnosis and race, the largest differences in survival 
between whites and blacks were observed for patients with OPSCCs ages 40 to 49 years 
(73.2% and. 40%, respectively), 50 to 59 years (67.6% and 38.6%, respectively), and <40 
years (76% and 51.7%, respectively) at the time of diagnosis. In addition, large differences 
in survival between whites and blacks were observed for men ages 40 to 49 years with 
penile SCCs (58.5% and 34.5%, respectively) (Fig. 1).
For cancers that occurred among both men and women, more than one-half of anal and 
rectal SCCs occurred among women compared with only 20% of OPSCCs (Table 1). 
Compared with men, women had higher 5-year relative survival for anal SCCs (69.3% and 
59.8%, respectively) and rectal SCCs (61.2% and 45.5%, respectively) and slightly 
decreased survival for OPSCCs (Table 2). The greatest differences in survival by sex were 
observed for rectal SCCs.
More than one-third of all HPV-associated cancers were diagnosed at localized stage, with 
the exception of OPSCCs, in which 16% were diagnosed at localized stage (Table 1). The 5-
year relative survival rate was higher for all HPV-associated cancers diagnosed at localized 
stage and decreased for cancers diagnosed at regional and distant stages. The 5-year age-
standardized relative survival rate ranged from 59.4% to 86% for cancers diagnosed in 
localized stage, from 41.2% to 58.5% for cancers diagnosed in regional stage, and from 
13.3% to 31.7% for cancers diagnosed in distant stages. The shortest survival was observed 
for rectal SCCs diagnosed at distant stage (13.3%). The greatest differences in survival 
between cancers diagnosed in localized and distant stages were observed for vulvar SCCs 
(79% and 16.5%, respectively) and OPSCCs (59.4% and 30.8%, respectively) (Table 2). 
When examining 5-year relative survival by population characteristics and disease stage at 
diagnosis, the poorest survival was observed for men who had rectal SCCs and for patients 
aged ≥60 years who had rectal and vulvar SCCs diagnosed at distant stage (6.9%, 10.5%, 
and 10.9%, respectively) (Table 1).
DISCUSSION
This study is the largest population-based study of survival for HPV-associated cancers in 
the United States, covering 59% of the population. Previous studies covered a smaller 
number of the US population, ranging from <100 to approximately 50,000 cases, whereas 
the current analysis included 220,211 cases.22–30 Furthermore, this study is the first 
comprehensive survival analysis for all HPV-associated cancers that includes 7 cancer sites. 
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We report the highest 5-year age-standardized relative survival for cervical carcinomas, 
vulvar, and anal SCCs and the lowest for penile SCCs and OPSCCs. Our overall findings 
include higher survival rates for whites compared with blacks, with the largest differences 
observed among those with OPSCCs, as well as higher survival rates for those who had 
cancers diagnosed at localized stage compared with those diagnosed at regional or distant 
stages. In addition, although survival usually decreased with age, we observed slightly 
higher 5-year age-standardized relative survival rates for those diagnosed between ages 40 
and 49 years with vaginal SCC, vulvar SCC, and anal SCC compared with those diagnosed 
at age ≤40 years with these cancers, a finding that merits further investigation (eg, whether 
there were differences by sex or human immuno-deficiency virus status for anal SCCs).
More than two-thirds of cases in our study were cervical carcinomas or HPV-associated 
OPSCCs. For patients with cervical carcinoma, the 5-year relative survival rate was high, 
which may be because of screening and early detection (almost one-half of cervical 
carcinomas in our study were detected at localized stage). For patients with OPSCC, the 
survival rate was lower compared with that for patients with other HPV-associated cancers, 
which is concerning given the recent increase in OPSCCs as well as the lack of routinely 
recommended, population-based screening tests.31 Similar to previous findings, we report 
that most HPV-associated OPSCCs were observed among whites and men, and about one-
half occurred in patients aged ≤60 years.12,22,23,32,33 These findings, combined with the 
observation that survival was consistently lower among patients with OPSCC, is troubling. 
Furthermore, similar to the report by Goodman and colleagues, we observed that a large 
proportion of HPV-associated OPSCCs were diagnosed at regional stage; >60% of HPV-
associated OPSCCs, compared with <40% of other HPV-associated cancers, were diagnosed 
at regional stage.7 The few studies that have examined whether there is a difference in 
survival by HPV status among patients with OPSCC have indicated that patients with HPV-
positive OPSCC survive longer than those with HPV-negative OPSCC.7,32 We could not 
examine survival by HPV status, because our classification of HPV-associated cancers was 
based on histologic type and not on actual assessments of individual tumor status for the 
presence of HPV DNA.
For other rare HPV-associated cancers, we observed the highest survival for anal SCC and 
the lowest for penile SCC. The published evidence about survival from these cancers is 
limited and includes smaller populations as well as various definitions of HPV-associated 
cancers. In a study of HPV-associated anal cancers that included rectal SCCs in the United 
States, Joseph et al reported that more than one-half of these cancers were diagnosed in 
localized stage, similar to our findings. Those authors also observed higher survival among 
women compared with men and among whites compared with blacks.30 Relatively little is 
known about the epidemiology of penile SCCs, and recent survival studies for penile cancers 
are lacking.34 A small study representing 12% of the US population and with data from 
1973 through 1998 reported that the average duration of disease-specific survival was <5 
years and decreased for localized, regional, and distant tumors, which is similar to our 
findings of decreased survival with advanced stages of cancer at diagnosis.35
Several factors highlight the importance of primary prevention of HPV-associated cancers. 
First, the incidence of HPV-associated cancers increased during 2004 through 2012 in the 
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United States, indicating an increased burden from HPV infection.5 Second, the proportion 
of OPSCCs in all age groups with HPV-positive status increased from 21% before the 1990s 
to >70% today8,15,31,36; and, if increasing trends continue, then OPSCC will become the 
most common HPV-associated cancer by 2020.31 Third, our study demonstrated that 
survival from HPV-associated cancers is poor compared with survival from all sites 
combined (67%) and compared with other cancers, such as breast cancers (90%) and 
prostate cancers (99%).37 In the absence of routine screening recommendations for any 
HPV-associated cancers, with the exception of cervical carcinomas, primary prevention 
through HPV vaccine is essential, especially for OPSCC, in which there is an increasing 
trend in incidence. HPV vaccines are approved and recommended for use among both boys 
and girls.38 Beyond primary prevention, assessing tumor HPV status is essential for OPSCC 
management and treatment, because some studies have noted differential responses to 
therapy in HPV-positive versus HPV-negative head and neck cancers.23,31,39–42
There are a few limitations to our study. The main limitation includes the classification of 
HPV-associated cancers, which was based on histologic criteria and not on actual assessment 
of individual tumor status for the presence of HPV DNA. In addition, we were not able to 
examine survival for any other racial/ethnic groups, because current life tables are only 
available for whites and blacks. Although, to our knowledge, this is the largest study to date 
of survival for HPV-associated cancers among blacks, the 95% CIs were wider for blacks 
than for whites, indicating that comparisons should be made with caution. Finally, treatment 
data were not available; therefore, we were not able to account for treatment differences in 
this analysis.
Although it is not a limitation, it is important to note that relative survival is not disease-
specific and is a net survival measure representing the likelihood that a patient will not die 
from causes associated specifically with the cancer under study. Furthermore, patients with 
cancer can die from comorbidities unrelated to their cancer diagnosis. A recent study 
concluded that, of all deaths that occurred in patients diagnosed with breast, prostate, colon, 
and rectal cancers at localized stage, a small proportion were because of cancer compared 
with other comorbidities, and the proportions of death from cancer increased with increasing 
stages of cancer at diagnosis.43
On the basis of the largest population-based study of survival for HPV-associated cancers in 
the United States, we observed large disparities in relative survival for HPV-associated 
cancers by sex, race, and age, especially by race and age for penile and oropharyngeal SCCs 
and by sex for rectal SCCs. HPV vaccination and improved access to screening and 
treatment, especially among groups that experience higher incidence and lower survival, 
may reduce disparities in survival from HPV-associated cancers.
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Figure 1. 
Age-standardized 5-year relative survival is illustrated for human papillomavirus (HPV)-
associated cancers by race and age at diagnosis (data from the National Program of Cancer 
Registries, 2001–2011). Cervical carcinomas were age standardized to the International 
Cancer Survival Standard 2 (ages ≥15 years). Vaginal, vulvar, penile, anal, rectal, and 
oropharyngeal squamous cell carcinomas (SCCs) were age standardized to the International 
Cancer Survival Standard 1 (ages ≥15 years). Data from the National Program of Cancer 
Registries (2001–2011) were compiled from 27 population-based cancer registries that 
participate in the National Program of Cancer Registries, meet the data-quality standards for 
inclusion in US Cancer Statistics, and meet the criteria for inclusion in the survival data set, 
which covers approximately 59% of the US population. Note that statistics could not be 
displayed for blacks aged <40 years for penile SCC because there were <25 patients.
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t c
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l C
an
ce
r S
ur
vi
v
al
 S
ta
nd
ar
d 
2 
(ag
es 
≥1
5 y
ea
rs)
.
f T
he
 n
um
be
rs
 m
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 c
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h 
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